Loading publications…
The last 5 uploaded publications
Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial
Edmond M. Kwan, Sarah W.S. Ng, Sofie H. Tolmeijer, Louise Emmett, Shahneen Sandhu, James Buteau, Amir Iravani, Anthony M. Joshua, Roslyn J. Francis, Vinod Vijay Subhash, Sze-Ting Lee, Andrew M. Scott, Andrew Martin, Martin R. Stockler, Gráinne Donnellan, Matti Annala, Cameron Herberts, Ian D. Davis, Michael S. Hofman, Arun Azad, Alexander W. Wyatt (2025). Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial. , DOI: https://doi.org/10.1038/s41591-025-03704-9.
Article62 days agoClonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving <sup>177</sup> Lu-PSMA-617 or cabazitaxel: An exploratory post-hoc analysis of a randomized phase II trial (TheraP; ANZUP 1603).
Aslı D. Munzur, Cameron Herberts, Edmond M. Kwan, Louise Emmett, Shahneen Sandhu, James Buteau, Amir Iravani, Anthony M. Joshua, Roslyn J. Francis, Sze Ting Lee, Andrew M. Scott, Andrew Martin, Martin R. Stockler, Alison Yan Zhang, Scott Williams, Jack V. W. Bacon, Arun Azad, Ian D. Davis, Michael S. Hofman, Alexander W. Wyatt (2025). Clonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving <sup>177</sup> Lu-PSMA-617 or cabazitaxel: An exploratory post-hoc analysis of a randomized phase II trial (TheraP; ANZUP 1603).. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.5020.
Article62 days agoImaging for assessment of cancer treatment response to immune checkpoint inhibitors can be complementary in identifying hypophysitis
Anna Galligan, Amir Iravani, Arian Lasocki, Roslyn Wallace, Alison M. Weppler, Nirupa Sachithanandan, Cherie Chiang, Peter G. Colman, John M. Wentworth, Lavinia Spain, George Au‐Yeung, Belinda Lee, Thomas W. H. Kay, Rodney J. Hicks, Shahneen Sandhu, Balasubramanian Krishnamurthy (2023). Imaging for assessment of cancer treatment response to immune checkpoint inhibitors can be complementary in identifying hypophysitis. , 14, DOI: https://doi.org/10.3389/fendo.2023.1295865.
Article62 days agoValidation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [177Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 Trial
Andrei Gafita, Andrew Martin, Louise Emmett, Matthias Eiber, Amir Iravani, Wolfgang P. Fendler, James Buteau, Shahneen Sandhu, Arun Azad, Ken Herrmann, Martin R. Stockler, Ian D. Davis, Michael S. Hofman (2024). Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [177Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 Trial. , DOI: https://doi.org/10.1016/j.euo.2024.03.009.
Article62 days agoNovel radionuclide therapy combinations in prostate cancer
Andrisha–Jade Inderjeeth, Amir Iravani, Shalini Subramaniam, Ciara Conduit, Shahneen Sandhu (2023). Novel radionuclide therapy combinations in prostate cancer. , 15, DOI: https://doi.org/10.1177/17588359231187202.
Article62 days ago